Investigate / A
Understand AGILENT TECHNOLOGIES, INC.
Can Agilent's broad laboratory portfolio and recent pathology acquisition perform if customer spending softens and costs remain relatively fixed?
Snapshot reviewed 2026-10-02. Source published 2026-09-01. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / A
Ask better questions. Keep the evidence.
Explore the available sources for AGILENT TECHNOLOGIES, INC., then keep what deserves another look.
01 Investor activity
Who reports owning A?
3 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Agilent sells instruments, software, services and consumables that laboratories use across their workflows, so customers pay for both analytical equipment and the supplies and services that support it.
Latticework interpretation
What could support the case?
If the pathology acquisition expands the portfolio as described, Agilent might serve clinical and research pathology customers more fully, which could support its Life Sciences and Diagnostics Markets segment.
Latticework interpretation
What could break the case?
If customer markets decline and pricing pressure intensifies, relatively fixed operating expenses could reduce operating margins if Agilent cannot respond quickly enough.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Agilent sells instruments, software, services and consumables that laboratories use across their workflows, so customers pay for both analytical equipment and the supplies and services that support it.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-07-31. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-05-01–2026-07-31; prior 2025-05-01–2025-07-31Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $1,878m | $1,738m |
| Operating income ↗Quarter: 2026-05-01–2026-07-31; prior 2025-05-01–2025-07-31Both values reported in the current filing. | $444m | $360m |
| Net income ↗Quarter: 2026-05-01–2026-07-31; prior 2025-05-01–2025-07-31Both values reported in the current filing. | $362m | $336m |
| Operating cash flow ↗Nine months (year to date): 2025-11-01–2026-07-31; prior 2024-11-01–2025-07-31Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $1,064m | $1,014m |
3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If the pathology acquisition expands the portfolio as described, Agilent might serve clinical and research pathology customers more fully, which could support its Life Sciences and Diagnostics Markets segment.
Supporting filing ↗The strongest caution
If customer markets decline and pricing pressure intensifies, relatively fixed operating expenses could reduce operating margins if Agilent cannot respond quickly enough.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How is the Biocare acquisition being integrated?
Starting evidence: The acquisition is described as expanding the pathology portfolio, so integration outcomes may affect whether the intended customer benefits materialize.
Investigate next: Review later filings and management commentary on Biocare's contribution, integration progress and any acquisition-related costs.
Read the supporting filing ↗How exposed is demand to order timing and cancellations?
Starting evidence: Quarterly results depend heavily on the volume and timing of orders, which are difficult to forecast and may be cancelled by customers.
Investigate next: Compare backlog, order trends and any disclosed cancellations across recent quarters and segments.
Read the supporting filing ↗How durable are the tariff mitigation measures?
Starting evidence: Management says it mitigated tariff effects through supply chain optimization, pricing actions and cost initiatives while monitoring changing trade conditions.
Investigate next: Examine disclosures on tariff costs, refund claims, pricing actions and sourcing changes, and how each affects margins.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.